Filed by Sanofi-Aventis
                                  Pursuant to Rule 165 and Rule 425(a) under the
                                           United States Securities Act of 1933,
                                                                      as amended

                                                        Subject Company: Aventis
                                                   Commission File No. 001-10378
                                                        Date: September 22, 2004


     On  September  22,  2004,  Sanofi-Aventis  issued the  following  two press
releases.

     In connection with its acquisition of Aventis, Sanofi-Aventis has announced
that  it  is  studying  the   feasibility  of  merging  Aventis  with  and  into
Sanofi-Aventis,  with Sanofi-Aventis continuing as the surviving corporation. In
connection with any merger of Aventis into  Sanofi-Aventis,  Sanofi-Aventis will
file a post-effective  amendment to its registration statement on Form F-4 (File
no.  333-112314),  which will include a prospectus  relating to the merger,  and
will file  additional  documents  with the SEC.  INVESTORS ARE URGED TO READ THE
REGISTRATION  STATEMENT,  INCLUDING  ANY  PRELIMINARY  PROSPECTUS  OR DEFINITIVE
PROSPECTUS  (WHEN  AVAILABLE)  RELATING  TO THE MERGER,  AND ANY OTHER  RELEVANT
DOCUMENTS FILED WITH THE SEC, INCLUDING ALL AMENDMENTS AND SUPPLEMENTS,  BECAUSE
THEY  WILL  CONTAIN  IMPORTANT  INFORMATION.  Free  copies  of the  registration
statement,  as well as other  relevant  documents  filed  with  the SEC,  may be
obtained  at the  SEC's  web  site  at  www.sec.gov.  At the  appropriate  time,
Sanofi-Aventis  will provide  investors  with  information  on how to obtain any
merger-related documents for free from Sanofi-Aventis or from its duly appointed
agents.



                                     * * * *




                             [SANOFI-AVENTIS LOGO]

                                                       Paris, September 22, 2004


                  NEW APPOINTMENTS IN THE SANOFI-AVENTIS GROUP


Further to the appointments of a hundred managers in  Pharmaceutical  Operations
at the  beginning of the month,  THE  SANOFI-AVENTIS  GROUP today  announced the
appointment of the managers in the following departments:

-        Scientific and Medical Affairs, headed by Gerard LE FUR
-        Finance, headed by Jean-Claude LEROY
-        Industrial Affairs, headed by Gilles LHERNOULD
-        Communications, headed by Nicole CRANOIS
-        Legal, headed by Dirk OLDENBURG
-        Audit and Internal Control Assessment, headed by Marie-Helene LAIMAY

The  announcement  of these  appointments  shows the rapid  continuation  of the
integration process within the new sanofi-aventis Group.


THE  SANOFI-AVENTIS  GROUP is the world's 3rd  largest  pharmaceutical  company,
ranking  number  1  in  Europe.   Backed  by  a  world-class  R&D  organization,
sanofi-aventis is developing leading positions in seven major therapeutic areas:
cardiovascular disease, thrombosis,  oncology, diabetes, central nervous system,
internal  medicine,  vaccines.  The  sanofi-aventis  Group  is  listed  in Paris
(EURONEXT : SAN) and in New York (NYSE : SNY).

Important Information
---------------------
In connection with its acquisition of Aventis, Sanofi-Aventis has announced that
it is studying the feasibility of merging Aventis with and into  Sanofi-Aventis,
with Sanofi-Aventis continuing as the surviving corporation.  In connection with
any  merger  of  Aventis  into   Sanofi-Aventis,   Sanofi-Aventis  will  file  a
post-effective  amendment  to its  registration  statement on Form F-4 (File no.
333-112314),  which will include a prospectus  relating to the merger,  and will
file  additional  documents  with  the  SEC.  INVESTORS  ARE  URGED  TO READ THE
REGISTRATION  STATEMENT,  INCLUDING  ANY  PRELIMINARY  PROSPECTUS  OR DEFINITIVE
PROSPECTUS  (WHEN  AVAILABLE)  RELATING  TO THE MERGER,  AND ANY OTHER  RELEVANT
DOCUMENTS FILED WITH THE SEC, INCLUDING ALL AMENDMENTS AND SUPPLEMENTS,  BECAUSE
THEY  WILL  CONTAIN  IMPORTANT  INFORMATION.  Free  copies  of the  registration
statement,  as well as other  relevant  documents  filed  with  the SEC,  may be
obtained  at the  SEC's  web  site  at  www.sec.gov.  At the  appropriate  time,
Sanofi-Aventis  will provide  investors  with  information  on how to obtain any
merger-related documents for free from Sanofi-Aventis or from its duly appointed
agents.



         Senior Vice President, Corporate Communications: Nicole Cranois
               - Vice President, Media Relations: Jean-Marc Podvin
               Tel: + 33.1.53.77.42.23 - Fax + 33.1.53.77.42.65 -
           174 avenue de France - 75013 Paris - www.sanofi-aventis.com


                                 [PRESS RELEASE GRAPHIC APPEARS ON SIDE OF PAGE]





                             [SANOFI-AVENTIS LOGO]

                                                       Paris, September 22, 2004


                  APPOINTMENTS AT THE COMMUNICATIONS DEPARTMENT
                           OF THE SANOFI-AVENTIS GROUP

THE   SANOFI-AVENTIS   GROUP  announced  today  the   appointments   within  the
Communications  department  of the  Group,  which is headed  by Nicole  CRANOIS,
Senior Vice President, Communications.

   - Jocelyne COUPAT,               Vice President, International Relations
   - Agnes GARCIA-GIBOT,            Vice President, Internal Communications
                                    and Corporate Image
   - Michel JOLY,                   Vice President, Product PR
   - William BRATTON,               Deputy Vice President, Product PR
   - Jean-Marc PODVIN,              Vice President, Media Relations
   - Robert SEBBAG,                 Vice President, Solidarity mission on access
                                    to  medicine

Are also members of the Communications Management Committee:

   - Xavier LEGRAND DU LAURENS,          Vice President, Communications France
   - Miriam HENN,                        Vice President, Communications Germany
   - Charles F. ROUSE,                   Vice President, Communications USA.

THE  SANOFI-AVENTIS  GROUP is the world's 3rd  largest  pharmaceutical  company,
ranking  number  1  in  Europe.   Backed  by  a  world-class  R&D  organization,
sanofi-aventis is developing leading positions in seven major therapeutic areas:
cardiovascular disease, thrombosis,  oncology, diabetes, central nervous system,
internal  medicine,  vaccines.  The  sanofi-aventis  Group  is  listed  in Paris
(EURONEXT : SAN) and in New York (NYSE : SNY).

Important Information
---------------------

In connection with its acquisition of Aventis, Sanofi-Aventis has announced that
it is studying the feasibility of merging Aventis with and into  Sanofi-Aventis,
with Sanofi-Aventis continuing as the surviving corporation.  In connection with
any  merger  of  Aventis  into   Sanofi-Aventis,   Sanofi-Aventis  will  file  a
post-effective  amendment  to its  registration  statement on Form F-4 (File no.
333-112314),  which will include a prospectus  relating to the merger,  and will
file  additional  documents  with  the  SEC.  INVESTORS  ARE  URGED  TO READ THE
REGISTRATION  STATEMENT,  INCLUDING  ANY  PRELIMINARY  PROSPECTUS  OR DEFINITIVE
PROSPECTUS  (WHEN  AVAILABLE)  RELATING  TO THE MERGER,  AND ANY OTHER  RELEVANT
DOCUMENTS FILED WITH THE SEC, INCLUDING ALL AMENDMENTS AND SUPPLEMENTS,  BECAUSE
THEY  WILL  CONTAIN  IMPORTANT  INFORMATION.  Free  copies  of the  registration
statement,  as well as other  relevant  documents  filed  with  the SEC,  may be
obtained  at the  SEC's  web  site  at  www.sec.gov.  At the  appropriate  time,
Sanofi-Aventis  will provide  investors  with  information  on how to obtain any
merger-related documents for free from Sanofi-Aventis or from its duly appointed
agents.

         Senior Vice President, Corporate Communications: Nicole Cranois
               - Vice President, Media Relations: Jean-Marc Podvin
               Tel: + 33.1.53.77.42.23 - Fax + 33.1.53.77.42.65 -
           174 avenue de France - 75013 Paris - www.sanofi-aventis.com


                                 [PRESS RELEASE GRAPHIC APPEARS ON SIDE OF PAGE]